Thermo Fisher Scientific EGFR (Cetuximab) Recombinant Human Monoclonal Antibody (C225)

Thermo Fisher Scientific EGFR (Cetuximab) Recombinant Human Monoclonal Antibody (C225)

Applications and Tested Dilution

• Immunohistochemistry (IHC): Assay-dependent
• Immunocytochemistry (ICC/IF): Assay-dependent
• Flow Cytometry (Flow): Assay-dependent
• ELISA: Assay-dependent
• Functional Assay (FN): Assay-dependent
• Inhibition Assays (IA): Assay-dependent

Product Specifications

Product Specific Information

• Specificity: Non-therapeutic biosimilar antibody using the same variable region sequence as therapeutic Cetuximab. Recognizes human EGFR.
• Endotoxin Level: ≤ 1.0 EU/mg (LAL method).
• Purity: ≥95% monomer by analytical SEC.
• Product Preparation: Produced in an animal-free facility using in vitro, protein-free cell culture; purified via multi-step process including Protein A/G for low endotoxin and aggregate levels.
• Pathogen Testing: Tested negative for all pathogens listed in IDEXX IMPACT I Mouse Profile.
• Storage and Handling: Store sterile at 2–8°C for up to one month; for longer storage, aliquot and keep at -80°C. Avoid repeated freeze-thaw cycles.
• Tested Applications: Immunohistochemistry, Immunocytochemistry, Flow Cytometry, ELISA, CyTOF®, Blocking.

Target Information

Cetuximab (Erbitux) is a chimeric (mouse/human) monoclonal antibody approved by the FDA for treatment of metastatic colorectal cancer, non-small cell lung cancer, and head and neck cancer. It functions as an EGFR inhibitor binding to epidermal growth factor receptor (EGFR).

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.